Related Experiment Videos
[Angiogenesis in the neoplastic process]
Pneumonologia I Alergologia Polska
|January 1, 1993
Abstract:
Solid tumor growth is accompanied by neovascularisation. In the absence of neovascularisation most tumors might become dormant at a tiny diameter 2-3 mm. New capillary growth is elicited by a diffusible factors generated by malignant tumor cells and by host cells. The inhibition of angiogenesis may provide a form of cancer treatment, either substitutional or additional to the conventional form of therapy. The present review summarized the state of our knowledge on this topic, angiogenesis and tumor growth.
Insights
Tumor growth relies on new blood vessel formation (angiogenesis). Inhibiting this process offers a promising cancer treatment strategy, potentially complementing existing therapies.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Research
Context:
- Solid tumors require neovascularization to grow beyond a minimal size.
- Tumor-induced angiogenesis is driven by diffusible factors from tumor and host cells.
- Tumor dormancy is observed in avascular tumors smaller than 2-3 mm.
Purpose:
- To review the current understanding of angiogenesis in tumor growth.
- To explore the potential of anti-angiogenic therapies for cancer treatment.
Summary:
- Solid tumor progression is critically dependent on the formation of new blood vessels (neovascularization).
- Without neovascularization, tumors typically remain dormant at a small diameter.
- Factors released by malignant cells and host cells stimulate new capillary growth.
- Inhibiting angiogenesis presents a potential therapeutic strategy for cancer, either alone or in combination with conventional treatments.
Impact:
- Highlights angiogenesis as a key target for novel cancer therapies.
- Provides a comprehensive overview for researchers and clinicians in oncology.
- Supports the development of anti-angiogenic drugs as a new class of cancer treatments.